KAKAKU.COM
26.6.2024 15:01:31 CEST | Business Wire | Press release
Tabelog*2, one of Japan’s largest restaurant search and reservation sites, has launched an online reservation service for visitors to Japan, which supports English, Chinese (Simplified and Traditional) and Korean. With reservations available at over 35,000 restaurants, it is the largest service of its kind in Japan.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240626189960/en/
Reservation Flow (Graphic: Business Wire)
*1As of June 26, 2024, based on internal research. Largest restaurant reservation service (instant reservations) for visitors to Japan
*2Tabelog is operated by Kakaku.com, Inc. one of Japan’s leading Internet companies.
Tabelog’s online reservation service for overseas visitors
To offer a more convenient way to find and reserve restaurants for the growing number of visitors to Japan, we have launched an online restaurant reservation service where reservations can be made in English, Chinese (Traditional and Simplified), and Korean.
*According to the Japan National Tourism Organization, the number of visitors to Japan is expected to exceed 3 million in May 2024 (up 60% from the previous year).
Features of Tabelog’s service are as follows:
- Search for restaurants in Japan by specifying a location, cuisine, budget, and the date and time you want to make a reservation.
- Select a restaurant based on detailed information about the restaurant, including menu, photos, and reviews posted by Japanese users.
-
Check reservation availability using the calendar function and make online reservations directly on Tabelog.
*Online reservations are currently only available for set menus and require credit card registration. In addition, there is a system usage fee of 440 yen (incl. tax) per person per reservation.
“Japan is currently the destination of choice for travelers from around the world, and many of them want to experience Japan’s food culture. However, there is still a shortage of restaurants equipped to communicate with and take reservations from overseas visitors leading to a situation where only a handful of well-known restaurants are attracting visitors to Japan,” said Taku Kounoike, Head of Tabelog. “As a Japanese gourmet media, we want to support travelers in experiencing the deeper charm of Japan, by showcasing a wide range of excellent restaurants across the country, and by providing a service that enables users to make online reservations. We sincerely hope that your travel experience in Japan will become more fulfilling than ever before.”
Links to the different language versions of Tabelog:
- English: https://tabelog.com/en/
- Simplified Chinese: https://tabelog.com/cn/
- Traditional Chinese: https://tabelog.com/tw/
- Korean: https://tabelog.com/kr/
*Ongoing modifications and improvements to the site may result in changes to the user interface and performance.
About Tabelog
Tabelog provides information on almost all restaurants in Japan, and users can choose restaurants catering to their specific preferences, based on information provided by the restaurants themselves, as well as reviews and photos posted by users. The service receives high marks from users for offering comprehensive information about restaurants and a highly convenient user interface. As of March 2024, it has become one of Japan’s largest restaurant search and reservation services, with approximately 93.5 million monthly users.
About Kakaku.com, Inc. (https://corporate.kakaku.com/?lang=en)
Established in 1997, Kakaku.com, Inc. (TOKYO:2371) is a Japanese internet company operating various web services, including the purchasing support site "Kakaku.com", the restaurant search and reservation service "Tabelog", and the comprehensive job search service "Kyujin Box". In April 2024, the company launched "Jobcube", a comprehensive search site for jobseekers, in the United States.
Service Overview: https://corporate.kakaku.com/company/service/?lang=en
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240626189960/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom